Outstanding Interim Results of Stentys International Clinical Study of 600 Heart Attack Patients

Published: Nov 08, 2011

PRINCETON, N.J. & PARIS--(BUSINESS WIRE)--STENTYS S.A. (STNT.PA), a medical technology company commercializing the world's first and only Self-Apposing™ Stent to treat Acute Myocardial Infarction (AMI), disclosed today data on 600 patients from its ongoing “APPOSITION III” international clinical study who underwent an examination 30 day after treatment of a severe heart attack.

Back to news